


# Researchers identify nanoparticles that could deliver therapeutic mRNA before birth

January 13 2021

---



Credit: CC0 Public Domain

Researchers at Children's Hospital of Philadelphia and the School of Engineering and Applied Science at the University of Pennsylvania have identified ionizable lipid nanoparticles that could be used to deliver mRNA as part of fetal therapy. The proof-of-concept study, published today in *Science Advances*, engineered and screened a number of lipid nanoparticle formulations for targeting mouse fetal organs and has laid

the groundwork for testing potential therapies to treat genetic diseases before birth.

"This is an important first step in identifying nonviral mediated approaches for delivering cutting-edge therapies before birth," said co-senior author William H. Peranteau, MD, an attending surgeon in the Division of General, Thoracic and Fetal Surgery and the Adzick-McCausland Distinguished Chair in Fetal and Pediatric Surgery at CHOP. "These [lipid nanoparticles](#) may provide a platform for in utero mRNA delivery, which would be used in therapies like fetal protein replacement and gene editing."

Michael J. Mitchell, Skirkanich Assistant Professor of Innovation in Penn Engineering's Department of Bioengineering, is the other co-senior author of the study.

Recent advances in DNA sequencing technology and prenatal diagnostics have made it possible to diagnose many [genetic diseases](#) before birth. Some of these diseases are treated by protein or enzyme replacement therapies after birth, but by then, some of the damaging effects of the disease have taken hold. Thus, applying therapies while the patient is still in the womb has the potential to be more effective for some conditions. The small fetal size allows for maximal therapeutic dosing, and the immature fetal immune system may be more tolerant of replacement therapy.

Of the potential vehicles for introducing therapeutic protein replacement, mRNA is distinct from other nucleic acids, such as DNA, because it does not need to enter the nucleus and can use the body's own machinery to produce the desired proteins. Currently, the common methods of nucleic acid delivery include viral vectors and nonviral approaches. Although viral vectors may be well-suited to gene therapy, they come with the potential risk of unwanted integration of the

transgene or parts of the viral vector in the recipient genome. Thus, there is an important need to develop safe and effective nonviral nucleic acid delivery technologies to treat prenatal diseases.

In order to identify potential nonviral delivery systems for therapeutic mRNA, the researchers engineered a library of lipid nanoparticles, small particles less than 100 nanometers in size that effectively enter cells in mouse fetal recipients. Each lipid nanoparticle formulation was used to encapsulate mRNA, which was administered to mouse fetuses. The researchers found that several of the lipid nanoparticles enabled functional mRNA delivery to fetal livers and that some of those lipid nanoparticles also delivered mRNA to the fetal lungs and intestines. They also assessed the lipid nanoparticles for toxicity and found them to be as safe or safer than existing formulations.

Having identified the lipid nanoparticles that were able to accumulate within fetal livers, lungs, and intestines with the highest efficiency and safety, the researchers also tested therapeutic potential of those designs by using them to deliver erythropoietin (EPO) mRNA, as the EPO protein is easily trackable. They found that EPO mRNA delivery to liver cells in mouse fetuses resulted in elevated levels of EPO protein in the fetal circulation, providing a model for protein replacement therapy via the liver using these lipid nanoparticles.

"A central challenge in the field of gene [therapy](#) is the delivery of [nucleic acids](#) to target cells and tissues, without causing side effects in healthy tissue. This is difficult to achieve in adult animals and humans, which have been studied extensively. Much less is known in terms of what is required to achieve in utero nucleic acid delivery," said Mitchell. "We are very excited by the initial results of our lipid nanoparticle technology to deliver mRNA in utero in safe and effective manner, which could open new avenues for [lipid nanoparticles](#) and mRNA therapeutics to treat diseases before birth."

**More information:** "Ionizable lipid nanoparticles for in utero mRNA delivery" *Science Advances* (2021). [DOI: 10.1126/sciadv.aba1028](https://doi.org/10.1126/sciadv.aba1028)

Provided by Children's Hospital of Philadelphia

Citation: Researchers identify nanoparticles that could deliver therapeutic mRNA before birth (2021, January 13) retrieved 19 September 2024 from <https://phys.org/news/2021-01-nanoparticles-therapeutic-mrna-birth.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.